Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants' spike protein-an in silico analysis

PLoS One. 2021 May 26;16(5):e0251426. doi: 10.1371/journal.pone.0251426. eCollection 2021.

Abstract

Two SARS-CoV-2 variants of concern showing increased transmissibility relative to the Wuhan virus have recently been identified. Although neither variant appears to cause more severe illness nor increased risk of death, the faster spread of the virus is a major threat. Using computational tools, we found that the new SARS-CoV-2 variants may acquire an increased transmissibility by increasing the propensity of its spike protein to expose the receptor binding domain via proteolysis, perhaps by neutrophil elastase and/or via reduced intramolecular interactions that contribute to the stability of the closed conformation of spike protein. This information leads to the identification of potential treatments to avert the imminent threat of these more transmittable SARS-CoV-2 variants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Angiotensin-Converting Enzyme 2 / chemistry
  • Angiotensin-Converting Enzyme 2 / metabolism
  • Antibodies, Neutralizing / immunology
  • COVID-19 / pathology
  • COVID-19 / virology
  • Humans
  • Molecular Dynamics Simulation
  • Mutation
  • Neutrophils / cytology
  • Neutrophils / metabolism
  • Pancreatic Elastase / metabolism*
  • Protein Binding
  • Protein Stability
  • Protein Structure, Tertiary
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / metabolism*
  • SARS-CoV-2 / pathogenicity
  • Sequence Alignment
  • Spike Glycoprotein, Coronavirus / chemistry
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • Spike Glycoprotein, Coronavirus / metabolism*

Substances

  • Antibodies, Neutralizing
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2
  • Pancreatic Elastase

Grants and funding

Supported in part by the 2020 COVID-19 Response: Drug and Vaccine Prototyping Grant from the Innovative Medicines Accelerator, Stanford University to D. M.-R. and by the SPARK at Stanford community. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.